

Robert E Hutchison

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3211644/publications.pdf>

Version: 2024-02-01

39
papers

995
citations

623188

14
h-index

476904

29
g-index

39
all docs

39
docs citations

39
times ranked

1609
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models. <i>Leukemia</i> , 2022, 36, 746-759.	3.3	10
2	Therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALK + ALCL. , 2021, , 141-159.		0
3	Surgeon Concordance in the Assessment of Resectability for Stage IA Nodular Lymphocyte Predominant Hodgkin Lymphoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, 246-247.	0.3	1
4	Crizotinib induces apoptosis and gene expression changes in ALK+ anaplastic large cell lymphoma cell lines; brentuximab synergizes and doxorubicin antagonizes. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27094.	0.8	7
5	<i><sc>STAT</sc>3</i> mutations are not sufficient to induce large granular lymphocytic leukaemia in mice. <i>British Journal of Haematology</i> , 2018, 180, 911-915.	1.2	16
6	Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26753.	0.8	18
7	73 Cell Cycle Analysis of Crizotinib and Doxorubicin Effect on ALK+ ALCL: "Tug of War". <i>American Journal of Clinical Pathology</i> , 2018, 149, S32-S32.	0.4	0
8	Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada. <i>American Journal of Clinical Pathology</i> , 2018, 150, 393-405.	0.4	6
9	Hmga2 promotes the development of myelofibrosis in Jak2V617F knockin mice by enhancing TGF- β 1 and Cxcl12 pathways. <i>Blood</i> , 2017, 130, 920-932.	0.6	19
10	Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26278.	0.8	43
11	Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma. <i>Blood Advances</i> , 2017, 1, 681-684.	2.5	27
12	Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2016, 34, 2372-2379.	0.8	56
13	Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm. <i>Blood</i> , 2016, 127, 3410-3423.	0.6	78
14	Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. <i>Journal of Clinical Oncology</i> , 2016, 34, 854-862.	0.8	154
15	Deletion of PTPN1 Promotes the Development of Myelofibrosis. <i>Blood</i> , 2016, 128, 795-795.	0.6	0
16	Expression of HMGA2 Cooperates with Jak2V617F in the Development of Myelofibrosis. <i>Blood</i> , 2016, 128, 797-797.	0.6	0
17	Immunohistochemical Expression of mTOR in Germinal Center and Nongerminal Center Group of Diffuse Large B-Cell Lymphoma: A Clinicopathological Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 159-163.	0.2	2
18	Critical Role of SHP2 in the Initiation and Maintenance of Myeloproliferative Neoplasms Evoked By JAK2V617F. <i>Blood</i> , 2015, 126, 483-483.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate-Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group Study AHOD0031. <i>Journal of Clinical Oncology</i> , 2014, 32, 3651-3658.	0.8	200
20	Bone Marrow Core Biopsy Adequacy and Variability in the United States and Canada: A Multicenter Retrospective Study. <i>Blood</i> , 2014, 124, 1316-1316.	0.6	1
21	Loss of EZH2 Inhibits Erythropoiesis and Accelerates the Development of Myelofibrosis in Jak2V617F Knock-in Mice. <i>Blood</i> , 2014, 124, 159-159.	0.6	0
22	Treatment of pediatric lymphocyte predominant Hodgkin lymphoma (LPHL): A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10000-10000.	0.8	1
23	Analysis of NF- κ B Pathway Proteins in Pediatric Hodgkin Lymphoma: Correlations with EBV Status and Clinical Outcome—A Children's Oncology Group Study. <i>Lymphoma</i> , 2012, 2012, 1-12.	0.2	1
24	ALK+ anaplastic large cell lymphoma exhibits phosphatidylinositol-3 kinase/akt activity with retained but inactivated PTEN—A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2012, 59, 440-447.	0.8	6
25	Treatment of pediatric stage IA lymphocyte-predominant Hodgkin lymphoma with surgical resection alone: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9524-9524.	0.8	8
26	Loss of Wild-Type Jak2 Allele Enhances Myeloid Cell Expansion and Accelerates Myelofibrosis in Jak2V617F Knock-in Mice. <i>Blood</i> , 2012, 120, 809-809.	0.6	0
27	Coordinate Regulation of NF- κ B Subunit Expression In Pediatric Hodgkin Lymphoma Patients with Rapid Early Response to Therapy, but Not Slow Early Response to Therapy. <i>Blood</i> , 2010, 116, 2680-2680.	0.6	1
28	AHOD0031: A Phase III Study of Dose-Intensive Therapy for Intermediate Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group. <i>Blood</i> , 2010, 116, 766-766.	0.6	14
29	Conditional Expression of Heterozygous or Homozygous Jak2V617F From Its Endogenous Promoter Induces a Polycythemia Vera-Like Disease.. <i>Blood</i> , 2009, 114, 437-437.	0.6	14
30	Non-Anaplastic peripheral T-cell lymphoma in childhood and adolescence: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2008, 51, 29-33.	0.8	64
31	Expression of Anaplastic Lymphoma Kinase, Tyrosine-Phosphorylated STAT3, and Associated Factors in Pediatric Anaplastic Large Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2007, 127, 770-778.	0.4	25
32	Advanced-Stage Large-Cell Lymphoma in Children and Adolescents: Results of a Randomized Trial Incorporating Intermediate-Dose Methotrexate and High-Dose Cytarabine in the Maintenance Phase of the APO Regimen: A Pediatric Oncology Group Phase III Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 541-547.	0.8	131
33	The Frozen Section Yesterday and Today: Pediatric Solid Tumors—Crucial Issues. <i>Pediatric and Developmental Pathology</i> , 2001, 4, 252-266.	0.5	9
34	Apoptotic index by Annexin V flow cytometry: Adjunct to morphologic and cytogenetic diagnosis of myelodysplastic syndromes. <i>Cytometry</i> , 2001, 46, 28-32.	1.8	40
35	Primary Nodal Marginal Zone B-Cell Lymphoma Arising From More Than One Clonal Neoplastic Population. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 1816-1819.	1.2	9
36	Thymoma mimicking lymphoblastic lymphoma: A pitfall in fine-needle aspiration biopsy interpretation. , 1996, 14, 165-171.		33

#	ARTICLE	IF	CITATIONS
37	Serum from patients with non-hodgkin's lymphoma(nhl) inhibits T-cell colony formation. American Journal of Hematology, 1987, 25, 143-153.	2.0	1
38	A Man with Anemia and Lymphocytosis. , 0, , 371-377.		0
39	A Woman with Fatigue and Pallor. , 0, , 425-433.		0